{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:04:03Z","timestamp":1792728243695,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jgar.2018.07.010","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T20:29:19Z","timestamp":1532118559000},"page":"136-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Evaluation of ceftazidime\/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2264-0055","authenticated-orcid":false,"given":"Olga","family":"Rodr\u00edguez-N\u00fa\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6380-0377","authenticated-orcid":false,"given":"Marco","family":"Ripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Morata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"de la Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Feh\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pellic\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Valc\u00e1rcel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Puerta-Alcalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Garc\u00eda-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"del R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Mart\u00ednez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2018.07.010_bib0005","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.07.010_bib0010","article-title":"Salvage therapy with ceftolozane\u2013tazobactam for multidrug-resistant Pseudomonas aeruginosa infections","volume":"16","author":"Cast\u00f3n","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.07.010_bib0015","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ijantimicag.2017.04.001","article-title":"Use of ceftolozane\/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa","volume":"49","author":"Dinh","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.07.010_bib0020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane\u2013tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.07.010_bib0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2018.07.010_bib0030","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijantimicag.2016.11.005","article-title":"Clinical experience with ceftazidime\/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa","volume":"49","author":"Xipell","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.07.010_bib0035","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkq306","article-title":"In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters","volume":"65","author":"Mushtaq","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.07.010_bib0040","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2018.07.010_bib0045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01045-17","article-title":"Antimicrobial activity of ceftazidime\u2013avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from U. S. medical centers, 2013 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.07.010_bib0050","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime\u2013avibactam versus imipenem\u2013cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jgar.2018.07.010_bib0055","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.07.010_bib0060","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime\u2013avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.07.010_bib0065","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime\u2013avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.07.010_bib0070","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.07.010_bib0075","series-title":"27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 22\u201325 April 2017; Vienna, Austria","article-title":"Phase 3, randomized, multicentre study of ceftazidime\u2013avibactam versus meropenem in adults with nosocomial pneumonia including ventilator-associated pneumonia (REPROVE)","author":"Torres","year":"2017"},{"key":"10.1016\/j.jgar.2018.07.010_bib0080","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00875-17","article-title":"Multicenter evaluation of ceftazidime\u2013avibactam and ceftolozane\u2013tazobactam inhibitory activity against meropenem-nonsusceptible Pseudomonas aeruginosa from blood, respiratory tract, and wounds","volume":"61","author":"Grupper","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.07.010_bib0085","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1128\/AAC.00851-12","article-title":"Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime\u2013avibactam against Pseudomonas aeruginosa","volume":"56","author":"Crandon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.07.010_bib0090","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/AAC.04238-14","article-title":"Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime\u2013avibactam in archived isolates of Pseudomonas aeruginosa","volume":"59","author":"Winkler","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.07.010_bib0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/2047-2994-3-32","article-title":"Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis","volume":"3","author":"Nathwani","year":"2014","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jgar.2018.07.010_bib0100","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1128\/AAC.00750-12","article-title":"Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia","volume":"56","author":"Morata","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.07.010_bib0105","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam against \u03b2-lactam resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518301425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518301425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T12:31:00Z","timestamp":1544099460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716518301425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":21,"alternative-id":["S2213716518301425"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2018.07.010","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733712838.793555357","asserted-by":"object"}]},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of ceftazidime\/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2018.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}